Brief: Medrx announces phase I clinical trials result of MRX-5LBT in US
30/05/2016 07:21
May 30 (Reuters) - Medrx Co Ltd 4586.T :
* Says the clinical trials for MRX-5LBT have started in the
United States
* Says MRX-5LBT is a new type of medication that uses the
ILTS (Ionic Liquid Transdermal System), an exclusive
MEDRx technology that incorporates the company's ionic liquid
expertise
* Says the phase I clinical trials result shows that
MRX-5LBT is more permeable for lidocaine in hypodermis than
Lidoderm
Source text in Japanese: https://goo.gl/010ArO
Further company coverage: 4586.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 62674724;
Reuters Messaging: Cheng.Li@thomsonreuters.com@reuters.net))